Search research articles
Contact Us
Filters
Showing results (31-40 of 45) with videos related to
Page
of 5
Sort By:
Der Pathologe
|
December 22, 2005
[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma]
P Borchmann, K Behringer, A Josting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 1999
Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group
H Flechtner, J U Rüffer, M Henry-Amar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2002
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease
A Josting, C Rudolph, M Reiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2000
Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG
U Rueffer, M Sieber, A Josting, et al.
Annals of Hematology
|
August 12, 2003
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial
J-P Glossmann, A Engert, G Wassmer, et al.
Leukemia & Lymphoma
|
March 18, 2000
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma
A Josting, M Reiser, P D Wickramanayake, et al.
Journal of Hematotherapy & Stem Cell Research
|
September 12, 2000
Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF
C Scheid, M Reiser, A Draube, et al.
Bone Marrow Transplantation
|
July 22, 1999
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization
M Reiser, A Josting, A Draube, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 9, 2005
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study
A Josting, M Sieniawski, J-P Glossmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment
U Rueffer, K Breuer, A Josting, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 45) with videos related to
Sort By:
Page
of 5
Der Pathologe
|
December 22, 2005
[Secondary malignancies after successful primary treatment of malignant Hodgkin's lymphoma]
P Borchmann, K Behringer, A Josting, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 2, 1999
Quality of life assessment in Hodgkin's disease: a new comprehensive approach. First experiences from the EORTC/GELA and GHSG trials. EORTC Lymphoma Cooperative Group. Groupe D'Etude des Lymphomes de L'Adulte and German Hodgkin Study Group
H Flechtner, J U Rüffer, M Henry-Amar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 16, 2002
Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease
A Josting, C Rudolph, M Reiser, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 13, 2000
Prognostic factors for subdiaphragmatic involvement in clinical stage I-II supradiaphragmatic Hodgkin's disease: a retrospective analysis of the GHSG
U Rueffer, M Sieber, A Josting, et al.
Annals of Hematology
|
August 12, 2003
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy--results of a randomized trial
J-P Glossmann, A Engert, G Wassmer, et al.
Leukemia & Lymphoma
|
March 18, 2000
Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma
A Josting, M Reiser, P D Wickramanayake, et al.
Journal of Hematotherapy & Stem Cell Research
|
September 12, 2000
Mobilization with etoposide and granulocyte colony-stimulating factor can replace bone marrow harvesting in patients with malignant lymphoma who previously failed to mobilize sufficient stem cells with cyclophosphamide and G-CSF
C Scheid, M Reiser, A Draube, et al.
Bone Marrow Transplantation
|
July 22, 1999
Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization
M Reiser, A Josting, A Draube, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 9, 2005
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study
A Josting, M Sieniawski, J-P Glossmann, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 8, 2001
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment
U Rueffer, K Breuer, A Josting, et al.
Page
of 5